IV therapy is gaining popularity as a lifestyle wellness trend, but experts question its safety and necessity. Learn about ...

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

Researchers complete final analysis of a phase 3 study of men with hemophilia B receiving intravenous etranacogene dezaparvovec.

NICE has recommended obinutuzumab with mycophenolate for severe lupus nephritis after trials showed higher renal response and fewer flares.

A Pivotal Step in Optimizing the ADAPT 2.0 Technique for Speed and Simplicity with a Single System Setup CAMPBELL, Calif.--(BUSINESS WIRE)--January 28, 2026-- Imperative Care, Inc. today announced the ...

Central retinal artery occlusion can result in permanent vision loss. Effective treatment is lacking. We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving ...

The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients ...

Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...

New nanomaterial passes the blood-brain barrier to reduce damaging inflammation after the most common form of stroke. When ...

With a median follow-up of 4.2 years, patients receiving blinatumomab achieved a 4-year disease-free survival (DFS) of 83.3% ...

Valor Health in Johnson City has opened a new mental health clinic, offering ketamine-assisted therapy.